Erschienen in:
01.09.2012 | Hepatobiliary Tumors
Prognostic Significance of Antithrombin III Levels for Outcomes in Patients with Hepatocellular Carcinoma After Curative Hepatectomy
verfasst von:
Hiroshi Iwako, MD, Hirotaka Tashiro, MD, Hironobu Amano, MD, Yoshisato Tanimoto, MD, Akihiko Oshita, MD, Tsuyoshi Kobayashi, MD, Shintaro Kuroda, MD, Hirofumi Tazawa, MD, Junko Nambu, MD, Yoshihiro Mikuriya, MD, Tomoyuki Abe, MD, Hideki Ohdan, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2012
Einloggen, um Zugang zu erhalten
Abstract
Background
Although several studies have shown that serum antithrombin III (ATIII) has anti-inflammatory effects, the prognostic value of ATIII in HCC is unknown. We investigated the influence of preoperative ATIII levels on the outcome of patients who underwent hepatectomy for hepatocellular carcinoma (HCC).
Methods
Data from 440 patients (314 patients with ATIII ≥70 % and 126 patients with ATIII <70 %) who underwent curative hepatectomy for HCC were retrospectively collected and analyzed. To overcome bias due to the different distribution of covariates for the 2 groups, propensity score matching was performed on the patients, and outcomes were compared.
Results
The propensity score analysis revealed that 65 patients with ATIII of ≥70 % (group 1) and 65 patients with ATIII of <70 % (group 2) had the same preoperative and operative characteristics (excluding the ATIII level). The overall survival rate and the disease-free survival rate was significantly higher in group 1 than in group 2 (P = 0.005 and 0.011, respectively). Multivariate analysis showed that ATIII was a significant favorable factor for overall survival and disease-free survival of patients with HCC after curative hepatectomy.
Conclusions
The prognosis of patients with HCC was found to be associated with preoperative antithrombin III levels. ATIII may be useful for predicting outcomes of patients with HCC after curative hepatectomy.